CoChat

Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Background: The development of chimeric antigen receptor (CAR)-T cell therapy has revolutionized treatment outcomes in patients with lymphoid malignancies. However, several studies have reported a relatively high rate of infection in adult patients following CD19-targeting CAR T-cell therapy, particularly in the first 28 days. Notably, acute human herpesvirus 6 B (HHV6B) reactivation occurs in up to two-thirds of allogeneic hematopoietic stem cell transplantation patients. Case presentations: Herein, we describe a report of HHV6B encephalitis/myelitis in three patients with relapsed/refractory diffuse large B-cell lymphoma post CAR T-cell therapy. All three patients received multiple lines of prior treatment (range: 2–9 lines). All patients presented with fever that persisted for at least 2 weeks after CAR-T cell infusion (CTI). Both the onset time and duration were similar to those of the cytokine release syndrome (CRS); nevertheless, the CRS grades of the patients were low (grade 1 or 2). Delirium and memory loss after CTI were the earliest notable mental presentations. Neurological manifestations progressed rapidly, with patients experiencing varying degrees of impaired consciousness, seizures, and coma. Back pain, lumbago, lower limb weakness and uroschesis were also observed in Patient 3, indicating myelitis. High HHV6B loads were detected in all Cerebral spinal fluid (CSF) samples using metagenomic next-generation sequencing (mNGS). Only one patient required high-activity antivirals and IgG intravenous pulse treatment finally recovered, whereas the other two patients died from HHV6B encephalitis. Conclusion: Considering its fatal potential, HHV6B encephalitis/myelitis should be urgently diagnosed post CAR-T cell-based therapy. Furthermore, hematologists should differentially diagnose these conditions from CRS or other immunotherapy-related neurotoxicities as early as possible. The results of this study demonstrate the potential of mNGS in the early diagnosis of HHV6B infection, particularly when the organism is difficult to culture.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fneur.2024.1334000

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Timeline from the diagnosis of lymphoma, through the course of treatment, to the diagnosis of HHV6B encephalitis via lumbar puncture with mNGS. ASCT, Autologous Stem Cell Transplantation; auto, autologous; allo, allogeneic; LP, lumbar puncture; mos., months; d, day(s).
Figure 1 Timeline from the diagnosis of lymphoma, through the course of treatment, to the diagnosis of HHV6B encephalitis via lumbar puncture with mNGS. ASCT, Autologous Stem Cell Transplantation; auto, autologous; allo, allogeneic; LP, lumbar puncture; mos., months; d, day(s).CC BY · PubMed Central
Figure 2 Features of clinical presentations and laboratory examinations. (A) Clinical presentations of HHV6 reactivation patients; S, SCI, Stem Cell Infusion; (C), CTI; G, IVIgG. (B) mNGS of CSF samples of the patients. The identified sequence read numbers corresponding to HHV6B were 9,605, 41,626, and 126,904, with genomic coverages of 72.55, 83.32, and 87.5%, respectively. (C) Trends of cytokines both in serum and CSF. The units are as follows: IL2R: U/mL; IL1β, IL6, IL8, IL10, TNFα: pg./mL. (D) Biochemistry results of CSF.
Figure 2 Features of clinical presentations and laboratory examinations. (A) Clinical presentations of HHV6 reactivation patients; S, SCI, Stem Cell Infusion; (C), CTI; G, IVIgG. (B) mNGS of CSF samples of the patients. The identified sequence read numbers corresponding to HHV6B were 9,605, 41,626, and 126,904, with genomic coverages of 72.55, 83.32, and 87.5%, respectively. (C) Trends of cytokines both in serum and CSF. The units are as follows: IL2R: U/mL; IL1β, IL6, IL8, IL10, TNFα: pg./mL. (D) Biochemistry results of CSF.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 14

Metadata

Authors
Li, N., Zhang, R., Wang, J., Zhu, X., Meng, F., Cao, Y., Wang, G., & Yang, Y.
Affiliations
Tongji Hospital (CN)
Corresponding author
  • Wang, Gaoxiang
  • Yang, Yang
Venue
Frontiers in Neurology
Published
2024-02-29
Volume
15
Pages
1334000-1334000
ISSN
1664-2295 (ISSN-L)
OpenAlex
W4392292739
Cited by
14
References
36
Citations by year
2026: 2 · 2025: 10 · 2024: 2
FWCI
4.27
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82000176, 81830008, 81630006, 81570197)
  • Tongji University
Topics
  • Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
Keywords
CAR T-cell therapy, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, viral reactivation, cytokine release syndrome, differential diagnosis, metagenomic next-generation sequencing, antiviral therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma. https://app.cochat.ai/papers/10.3389/fneur.2024.1334000
The paper
Li, N., Zhang, R., Wang, J., Zhu, X., Meng, F., Cao, Y., Wang, G., & Yang, Y. (2024). Case report: Acute HHV6B encephalitis/myelitis post CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma. Frontiers in Neurology. https://doi.org/10.3389/fneur.2024.1334000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.